Conditions

Additive glucose-lowering effect of a dipeptidyl peptidase-4 (DPP4) inhibitor and an alpha-glucosidase inhibitor (AGI) might be beneficial in patients with T2DM.

Once-weekly injectable suspension can provide as much benefit as traditional twice-daily dosing.

New SGLT-2 inhibitor can be used as add-on therapy to provide better improvement in HbA1C in patients with type 2 diabetes.

Patients with type 2 diabetes usually do not die from diabetes, but from cardiovascular disease and strokes.

Study finds linoleic acid has long-term benefits in diabetes prevention, arachidonic acid not harmful.

Statin therapy may be elevating risk of type 2 diabetes in high-risk adults.

Study compares effectiveness of oral GLP-1 medication over injection.

Determining which patients benefit most from lifestyle, metformin interventions may improve individualized care decisions.

By Sheri R. Colberg, PhD: Much of the research on length of life for individuals living with type 1 diabetes is pessimistic, which makes a new study released recently a breath of fresh air. Data were collected for the ongoing nationwide, multicenter, Finnish Diabetic Nephropathy (FinnDiane) Study that tracked the death rate of 2,639 study participants.

Study finds diabetes complications and mortality may be better predicted with elevated 1-hour blood glucose levels compared with 2-hour blood glucose levels.